Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Long-Acting Opioid REMS Tally: FDA Lists 12 Brand, 23 Generic

Executive Summary

Nineteen companies will implement individual Risk Evaluation and Mitigation Strategies for long-acting/extended-release opioid products that are subject to the class-wide REMS unveiled by FDA July 9.

You may also be interested in...



Depomed To Make Treasure Out of J&J Trash With Nucynta Buy

Depomed is leveraging all its value to bet on a drug that was virtually ignored by its big pharma owner with its billion-dollar buy of Janssen’s Nucynta.

FDA Rejects Endo’s Deadline On Opana ER Petition; Impax Product May Become New RLD

Endo files suit against FDA seeking preliminary injunction to require FDA to say whether Endo’s withdrawal of non-crush resistant Opana ER was for safety reasons; FDA contends it has until May 10, 2013 to make this decision.

Brand And Generic Opioid Makers Agree: FDA Should Issue Guidance On Tamper Resistance

But Purdue and Teva disagree on the key question of whether a generic of a tamper-resistant analgesic must have the same dosage form as the reference-listed brand-name drug.

Related Content

Topics

UsernamePublicRestriction

Register

PS054592

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel